Real-World Data Show 2-Year Survival Predicts Long-Term Survival for Metastatic Germ-Cell Testicular Cancer
Contemporary treatment has led to improvements in survival for all patients with metastatic testicular germ-cell tumors (GCTs), including poor-risk patients, although they still have worse survival. A new study shows that if poor-risk patients receive curative therapy and survive for at least 2 years, their survival approaches that of favorable-risk and intermediate-risk patients. The study supports no further routine scanning 2 years after diagnosis in surviving patients.
Cabozantinib Improves on Standard of Care for Second-Line Treatment of Patients with Advanced Renal-Cell Carcinoma
Cabozantinib (Cabometyx) achieved superior progression-free survival (PFS) versus standard treatment with everolimus in patients with previously treated advanced renal-cell carcinoma in an updated analysis of the phase 3 METEOR trial, the results of which were reported at the 2016 Genitourinary Cancers Symposium.
Experience at a high-volume cancer center suggests that nonstereotactic body radiotherapy external beam reirradiation of the pelvis for cancer recurrence or for a second genitourinary malignancy is safe in patients with advanced cancer, and can achieve excellent and durable palliation of symptoms without severe radiation-induced morbidity. These patients are typically near the end of life, and palliation of their symptoms improves the quality of their remaining life.
Results 1 - 3 of 3